Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals

Cardiovascular Therapeutics

Volumn 28, Issue 6, 2010, Pages 356-360

  Metterlein, T ^a,b   Schuster, F ^a   Tadda, L ^a   Hager, M ^a   Roewer, N ^a   Anetseder, M ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Malignant hyperthermia; Myotoxicity; Statins

Indexed keywords

ATORVASTATIN; CALCIUM; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; SOLVENT;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL VIABILITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FORCE TRANSDUCER; IN VITRO STUDY; MALE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE CONTRACTURE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOPSY; CALCIUM; ELECTRIC STIMULATION; FEMALE; GEMFIBROZIL; GENOTYPE; HEPTANOIC ACIDS; HOMEOSTASIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOMETRIC CONTRACTION; MALE; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; PHENOTYPE; PYRROLES; RHABDOMYOLYSIS; SIMVASTATIN; SWINE; TIME FACTORS;

EID: 78449238670     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00237.x     Document Type: Article

References (26)

1. Jasinska M, Owczarek J, Orszulak-Michalak D,. Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007; 59: 483 - 499.
2. Clark LT,. Treating dyslipidemia with statins: The risk-benefit profile. Am Heart J 2003; 145: 387 - 396.
3. Thompson PD, Clarkson P, Karas RH,. Statin-associated myopathy. JAMA 2003; 289: 1681 - 1690.
4. Omar MA, Wilson JP, Cox TS,. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096 - 1107.
5. Guis S, Mattei JP, Liote F,. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 2003; 17: 877 - 907.
6. Willis RA, Folkers K, Tucker JL, Ye CQ, Xia LJ, Tamagawa H., Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A 1990; 87: 8928 - 8930. (Pubitemid 120007622)
7. Phillips PS, Haas RH, Bannykh S, et al,. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581 - 585.
8. Schaefer WH, Lawrence JW, Loughlin AF, et al,. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004; 194: 10 - 23.
9. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK,. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94: 109 - 110.
10. Laaksonen R, Jokelainen K, Laakso J, et al,. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851 - 854.
11. Sirvent P, Mercier J, Lacampagne A,. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008; 8: 333 - 338.
12. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC,. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/ mitochondria Ca2+-release system. J Pharmacol Exp Ther 2007; 321: 626 - 634.
13. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M,. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005; 314: 1032 - 1041.
14. Steinfath M, Wappler F, Scholz J,. Malignant hyperthermia. General, clinical and experimental aspects. Anaesthesist 2002; 51: 328 - 345.
15. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267 - 1269.
16. Wappler F, Roewer N, Kochling A, et al,. Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia. Anaesthesist 1995; 44: 538 - 544.
17. Wappler F, Anetseder M, Baur CP, et al,. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol 2003; 20: 528 - 536.
18. Gerbershagen MU, Fiege M, Weisshorn R, Kolodzie K, Schulte Am, Esch J, Wappler F,. Cumulative and bolus in vitro contracture testing with 4-chloro-3-ethylphenol in malignant hyperthermia positive and negative human skeletal muscles. Anesth Analg 2005; 101: 710 - 4, table.
19. Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Schulte Am, Esch J,. Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine. Eur J Anaesthesiol 2005; 22: 283 - 288.
20. Robinson RL, Anetseder MJ, Avan Broekhoven C, et al,. Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342 - 348.
21. Hall GM, Lucke JN, Lister D,. Malignant hyperthermia: Pearls out of swine? Br J Anaesth 1980; 52: 165 - 171.
22. Sirvent P, Mercier J, Vassort G, Lacampagne A,. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005; 329: 1067 - 1075.
23. Inoue R, Tanabe M, Kono K, Maruyama K, Ikemoto T, Endo M,. Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers. J Pharmacol Sci 2003; 93: 279 - 288.
24. Gerbershagen MU, Wappler F, Fiege M, Weihorn R, Kolodzie K, Schulte EJ,. Inhibition of sarcoplasmic Ca2+ adenosine triphosphatase in porcine skeletal muscle samples with cyclopiazonic acid enables in vitro malignant hyperthermia discrimination. Anesthesiology 2004; 101: 1475 - 1477.
25. Guis S, Bendahan D, Kozak-Ribbens G, et al,. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49: 237 - 238.
26. Guis S, Figarella-Branger D, Mattei JP, et al,. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006; 55: 551 - 557.